CNS-Targeted Leptin Therapy for Insulin-Independent Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 diabetes require active patient participation and insulin dosing, failing to maintain target blood glucose levels for most patients, leading to secondary health complications and high healthcare costs.
Innovation Solution
Administering a therapeutically effective amount of a leptin active, such as metreleptin, directly to the central nervous system, particularly targeting brain regions like the arcuate nucleus or hypothalamus, to regulate glucose metabolism independently of insulin levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin therapy is used to treat Type 1 diabetes, then blood glucose control can be achieved, but patient compliance and active participation are required leading to poor outcomes for most patients
Solution Approach 1:
The patent applies the self-service principle by using leptin therapy to enable the body's own metabolic systems to regulate blood glucose levels automatically. Leptin acts on the central nervous system to restore endogenous glucose control mechanisms, eliminating the need for continuous patient intervention and insulin administration that characterizes current insulin therapy approaches.
2Reliability
If insulin therapy is used to treat Type 1 diabetes, then blood glucose levels can be reduced, but secondary health complications and high healthcare costs increase
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the underlying leptin deficiency (which contributes to the disease state) into a therapeutic benefit. By administering leptin to address the root cause of metabolic dysfunction, the therapy not only controls blood glucose but also prevents secondary complications that arise from improper glucose control and insulin therapy side effects.
3Ease of manufacture
If current insulin therapy approaches are used, then diabetes treatment can be provided, but most patients fail to achieve target blood glucose control levels
Solution Approach 1:
The patent applies parameter changes by shifting the therapeutic target from insulin administration to leptin administration. This fundamental parameter change in the treatment approach addresses the underlying metabolic dysfunction more effectively, enabling patients to achieve target blood glucose control levels that have been elusive with insulin-only therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach normalizes blood glucose levels without insulin therapy, reducing insulin requirements and improving glucose control, potentially benefiting millions of Type 1 diabetes patients.
Implementation Method 1
Administering a therapeutically effective amount of a leptin active, such as metreleptin, directly to the central nervous system, particularly targeting brain regions like the arcuate nucleus or hypothalamus, to regulate glucose metabolism independently of insulin levels
Data Source
AI summary
The present disclosure provides methods for treating, ameliorating, and/or preventing glucose metabolism disorder by administering a leptin active delivered to the central nervous system (CNS), and in particular to brain regions. Also provided are compositions, kits and systems for practicing the methods.